在心房动和痴呆症中使用抗凝剂
Jonah Rocheeld1, Josef Kusayev2, William H Frishman1
1From the Department of Medicine, New York Medical College, Valhalla, NY.
Cardiology in review
|July 30, 2025
概括
对心脏动 (AF) 的抗凝药似乎对轻度痴呆症患者有益,降低死亡率. 然而,由于混合结果和出血风险,其在晚期痴呆症中的使用需要仔细,个性化评估.
科学领域:
- 老年病的医生 老年病的医生
- 心脏病学 心脏病学
- 神经学 神经学
背景情况:
- 在老年人群中,心房动 (AF) 和痴呆症经常同时发生.
- 对AF的抗凝剂可以预防血栓栓塞,但会增加出血风险,对老年人构成挑战.
- 在痴呆症患者中管理AF需要平衡中风预防与出血问题.
研究的目的:
- 审查有关AF和痴呆症患者抗凝剂的文献.
- 为了澄清临床指南管理AF在这个患者小组,考虑到出血风险.
- 评估抗凝药在不同程度认知障碍的老年患者的净益.
主要方法:
- 现有文献的叙述性审查.
- 对观察性队列研究,元分析和注册数据的分析.
- 评估临床结果,包括死亡率和出血事件.
主要成果:
- 抗凝血疗法得到了轻度至中度痴呆症患者多项研究的支持.
- 晚期痴呆症的结果是混合的,大多数研究表明中性到适度的死亡率益处.
- 直接口服抗凝剂可能比华法林具有优势,因为使用更容易,内出血风险更低.
结论:
- 抗凝药可能为AF和早期痴呆症患者提供净死亡益处.
- 在患有晚期痴呆症的老年患者中使用需要个性化风险-益处评估和考虑患者的目标.
- 进一步的研究,包括与痴呆症子组和生活质量措施的RCT至关重要.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
911
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
911
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Venous Thrombosis IV: Nursing Management
24
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
24
Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35


